By Fineline Cube 
AstraZeneca plc (NYSE: AZN) announced the official market launch in China of Tezspire (generic name: tezepelumab injection). The commercialization milestone brings China’s patients the first‑in‑class TSLP inhibitor for severe asthma and chronic rhinosinusitis with nasal polyps, following Chinese regulatory approval in March 2026.
Launch Milestone
| Item | Detail |
|---|---|
| Company | AstraZeneca plc (NYSE: AZN) |
| Product | Tezspire (tezepelumab injection) |
| Milestone | Official market launch in China |
| China Approval | March 2026, based on Phase III DIRECTION and WAYPOINT trials |
| Co‑Developer | Amgen |
| Announcement Date | 17 Aug 2026 |
Approved Indications in China
| Indication | Population & Setting |
|---|---|
| Severe Asthma | Maintenance treatment for adults and adolescents aged 12 and older |
| CRSwNP | In combination with intranasal corticosteroids for adults with chronic rhinosinusitis with nasal polyps inadequately controlled by systemic corticosteroids and/or surgery |
Drug Profile & Mechanism of Action
- Molecule: Tezepelumab, a first‑in‑class human monoclonal antibody co‑developed by AstraZeneca and Amgen
- Target: Inhibits the activity of thymic stromal lymphopoietin (TSLP), an epithelial cytokine positioned at the top of the inflammatory cascade
- Mechanism Advantage: By blocking TSLP upstream, tezepelumab addresses multiple downstream inflammatory pathways, supporting efficacy across asthma phenotypes regardless of type 2 inflammation biomarkers
- Evidence Base: China approval was based on positive results from two Phase III clinical trials, DIRECTION and WAYPOINT
Market Impact & Outlook
- First‑In‑Class Positioning: As the only TSLP inhibitor in the Chinese market, Tezspire holds a mechanistically differentiated position against established biologics targeting IL‑5, IL‑4/13, and IgE.
- Large Addressable Population: China has one of the world’s largest severe asthma populations, with substantial unmet need for biologic therapies; the added CRSwNP indication further expands the commercial opportunity.
- Broad‑Phenotype Reach: Upstream TSLP inhibition positions tezepelumab for patients across inflammatory phenotypes, including those poorly served by biomarker‑restricted biologics.
- Strategic China Commitment: The rapid progression from March approval to August launch underscores AstraZeneca’s continued investment in bringing innovative respiratory biologics to China, one of its largest global markets.
Forward-Looking Statements
This brief contains forward‑looking statements regarding commercialization, market adoption, and sales expectations for Tezspire (tezepelumab) in China. Actual results may differ due to risks including reimbursement dynamics, market adoption, and competitive developments in the biologic respiratory market.-Fineline Info & Tech